Simplex Trading
CRVS icon

Simplex Trading’s Corvus Pharmaceuticals CRVS Stock Holding History

Simplex Trading’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.59M Sell
106,400
-6,900
-6% -$95.8K ﹤0.01% 2264
2026
Q1 		$1.66M Buy
113,300
+88,100
+350% +$1.41M ﹤0.01% 2001
2025
Q4 		$194K Sell
25,200
-5,000
-17% -$39.4K ﹤0.01% 4265
2025
Q3 		$222K Buy
30,200
+18,200
+152% +$93.1K ﹤0.01% 4817
2025
Q2 		$48K Sell
12,000
-99,800
-89% -$363K ﹤0.01% 5957
2025
Q1 		$355K Sell
111,800
-351,700
-76% -$1.66M ﹤0.01% 3759
2024
Q4 		$2.48M Buy
463,500
+448,400
+2,970% +$3.35M ﹤0.01% 2009
2024
Q3 		$79K Buy
15,100
+11,000
+268% +$39.5K ﹤0.01% 5448
2024
Q2 		$7K Sell
4,100
-3,100
-43% -$5.78K ﹤0.01% 7652
2024
Q1 		$12K Sell
7,200
-600
-8% -$1.25K ﹤0.01% 7462
2023
Q4 		$13K Buy
7,800
+6,200
+388% +$9.06K ﹤0.01% 7234
2023
Q3 		$2K Sell
1,600
-3,300
-67% -$6.98K ﹤0.01% 8057
2023
Q2 		$11K Buy
4,900
+3,800
+345% +$7.89K ﹤0.01% 7300
2023
Q1 		$1K Sell
1,100
-34,300
-97% -$26.8K ﹤0.01% 8667
2022
Q4 		$30K Sell
35,400
-1,500
-4% -$1.33K ﹤0.01% 6456
2022
Q3 		$30K Buy
36,900
+24,100
+188% +$23K ﹤0.01% 7068
2022
Q2 		$12K Sell
12,800
-6,400
-33% -$7.85K ﹤0.01% 8113
2022
Q1 		$31K Buy
19,200
+12,500
+187% +$22.9K ﹤0.01% 7720
2021
Q4 		$16K Buy
6,700
+4,800
+253% +$18.6K ﹤0.01% 8603
2021
Q3 		$5K Hold
1,900
– – ﹤0.01% 9261
2021
Q2 		$5K Buy
1,900
+1,820
+2,275% +$5.01K ﹤0.01% 9444
2021
Q1 		$24K Buy
80
+65
+433% +$235 ﹤0.01% 7297
2020
Q4 		$5K Buy
+15
New +$60 ﹤0.01% 7702

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Simplex Trading's CRVS Position: Q2 2026 in Review

Simplex Trading increased its Corvus Pharmaceuticals (CRVS) stake by 166% in Q2 2026, buying an estimated $800K and bringing the position to 92,343 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2416.

Simplex Trading first reported a position in CRVS in Q1 2020 and has held it in 19 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Simplex Trading held 92,343 shares of Corvus Pharmaceuticals worth $1.38M as of Q2 2026.
  • Simplex Trading bought 57,620 Corvus Pharmaceuticals shares in Q2 2026, an estimated $800K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #2416 holding.
  • Simplex Trading first reported a position in Corvus Pharmaceuticals in Q1 2020 and has held it in 19 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.